Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT00928668
- Locations
- 🇨🇦
1222.4.103 UBC - Respiratory Medicine, Vancouver, British Columbia, Canada
🇨🇦1222.4.102, Saskatoon, Saskatchewan, Canada
🇨🇦1222.4.104 Department of Medicine, Health Sciences Centre, Hamilton, Ontario, Canada
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 894
- Registration Number
- NCT00926289
- Locations
- 🇺🇸
502.550.01007 Boehringer Ingelheim Investigational Site, Greensboro, North Carolina, United States
🇨🇳502.550.86002 Boehringer Ingelheim Investigational Site, Shanghai, China
🇨🇳502.550.86007 Boehringer Ingelheim Investigational Site, Tianjin, China
Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 567
- Registration Number
- NCT00915772
- Locations
- 🇨🇦
1218.52.11003 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
🇨🇦1218.52.11002 Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada
🇭🇷1218.52.38502 Boehringer Ingelheim Investigational Site, Karlovac, Croatia
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
- Conditions
- Hypertension
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2411
- Registration Number
- NCT00909038
- Locations
- 🇫🇷
Boehringer Ingelheim Investigator site 359, La Tour Du Crieu, France
🇫🇷Boehringer Ingelheim Investigator site 360, La Turballe, France
🇫🇷Boehringer Ingelheim Investigator site 361, La Varenne St Hilaire, France
Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2
- Conditions
- Neoplasms
- Interventions
- Drug: BIBW 2992 low (20mg) dosageDrug: BIBW 2992 medium (40mg) dosageDrug: BIBW 2992 high (50mg) dosage
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 55
- Registration Number
- NCT00906698
- Locations
- 🇫🇷
1200.69.3301 Boehringer Ingelheim Investigational Site, Toulouse Cedex, France
🇫🇷1200.69.3302 Boehringer Ingelheim Investigational Site, Villejuif Cedex, France
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 85
- Registration Number
- NCT00905489
- Locations
- 🇿🇦
1100.1518.2703 Boehringer Ingelheim Investigational Site, Parow Valley, South Africa
🇺🇸1100.1518.0001 Boehringer Ingelheim Investigational Site, Washington, District of Columbia, United States
🇺🇸1100.1518.0002 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: BI 207127 low dose + SOCDrug: BI 207127 middle dose +SOCDrug: BI 207127 high dose+SOCDrug: Placebo + SOC
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 75
- Registration Number
- NCT00905632
- Locations
- 🇫🇷
1241.7.3307A CHU de Grenoble, Grenoble cédex 9, France
🇫🇷1241.7.3303A Hôpital Claude Huriez, Lille, France
🇩🇪1241.7.49011 Boehringer Ingelheim Investigational Site, Freiburg, Germany
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 128
- Registration Number
- NCT00904839
- Locations
- 🇫🇷
1199.51.3306C Boehringer Ingelheim Investigational Site, Nice Cedex 2, France
🇫🇷1199.51.3305A Boehringer Ingelheim Investigational Site, Toulouse cedex 3, France
🇫🇷1199.51.3308B Boehringer Ingelheim Investigational Site, Saint Herblain, France
An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1095
- Registration Number
- NCT00904215
- Locations
- 🇰🇷
Boehringer ingelheim Investigational Site 4, Daegu, Korea, Republic of
🇰🇷Boehringer ingelheim Investigational Site 1, Daegu, Korea, Republic of
🇰🇷Boehringer ingelheim Investigational Site 9, Daejeon, Korea, Republic of
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
- Conditions
- HypertensionCardiovascular Diseases
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2012-08-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 211
- Registration Number
- NCT00904371
- Locations
- 🇸🇮
Boehringer Ingelheim Investigational Site 23, Golnik, Slovenia
🇸🇮Boehringer Ingelheim Investigational Site 24, Brezice, Slovenia
🇸🇮Boehringer Ingelheim Investigational Site 32, Golnik, Slovenia